PUBLISHER: Allied Market Research | PRODUCT CODE: 1344345
PUBLISHER: Allied Market Research | PRODUCT CODE: 1344345
According to a new report published by Allied Market Research, titled, "Clot Busting Drugs Market," The clot busting drugs market was valued at $28.6 billion in 2022, and is estimated to reach $60 billion by 2032, growing at a CAGR of 8.2% from 2023 to 2032.
Clot-busting drugs, also known as thrombolytic agents or fibrinolytic drugs, are medications used to dissolve blood clots in a medical condition called thrombosis. Thrombosis occurs when a blood clot forms within a blood vessel, obstructing the flow of blood. TPA is a thrombolytic or clot buster drug which is used to break up the clot that is causing a blockage or disruption in the flow of blood to the brain and aids in the restoration of blood flow to the affected part of the brain. Anticoagulants, such as heparin, warfarin, dabigatran, apixaban, and rivaroxaban, are medications that thin the blood and help to dissolve blood clots.
Treatment guidelines for cardiovascular disorders frequently need the use of clot-busting medicines in specific conditions.. Improved diagnostic procedures and increased awareness of the signs and symptoms of cardiovascular illnesses have resulted in earlier detection and treatment. To prevent harm in the future, early intervention typically includes the use of clot-busting medications. Overall, the rising prevalence of cardiovascular disorders, combined with innovations in treatment choices and increasing awareness, is boosting demand for clot busting drugs.
Careful and supervised administration is required due to unusual bleeding in the urine or stool, excessive bleeding from wounds or cuts, allergic reactions to clot buster medications, low blood pressure, and other side effects of clot busting medications. There may rarely be other options for controlling blood clots without the use of clot-busting drugs. For instance, in some situations of thrombosis of the deep veins or pulmonary embolism, anticoagulant medications (such as heparin or direct oral anticoagulants) may be used as the primary treatment. The availability of complementary therapies can affect the demand for clot-busting drugs.
The clot busting drugs market expansion is driven by various factors such as economic growth, increase in healthcare coverage, and rise in healthcare awareness. With increased healthcare spending, clot buster medications become more affordable and accessible, resulting in an increase in demand. Ongoing research and clinical trials to assess the efficacy and safety of clot buster medicines boosts the market expansion. As healthcare infrastructure improves and awareness of thrombotic disorders increases in various regions, there is a rising need for effective clot buster drugs. Pharmaceutical companies can tap into these markets by offering affordable and accessible treatment options.
The COVID-19 pandemic has had a substantial impact on many parts of healthcare, including the market for clot busting drugs. While COVID-19 predominantly affects the respiratory system, it can also cause a variety of cardiovascular problems, which may influence the demand for and use of clot-busting medications. COVID-19 has been linked to a higher risk of blood clot formation, which can result in disorders such as deep vein thrombosis (DVT), pulmonary embolism, and stroke. Studies have examined the effectiveness of different anticoagulant treatments, including clot-busting medications, in treating clotting issues associated with COVID-19. These investigations are expected to have an impact on market dynamics and clinical practices in the post-pandemic period.
The key players profiled in this report include: Pfizer Inc., Johnson & Johnson Services Inc, Sanofi, Dr. Reddy's Laboratories, Bayer AG, Boehringer Ingelheim Gmbh, Genentech Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., and Merck & Co.